ArticleFrontiers in molecular biosciences2025
Global trends and emerging insights in ocular tumor-associated metabolites: a bibliometric and visualization analysis.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to perform a comprehensive bibliometric analysis of global research on ocular tumor metabolomics, identifying key research trends, influential contributors, and emerging themes from 1995 to 2024. Methods: A systematic search was conducted in the Web of Science Core Collection (WoSCC) database to retrieve publications related to ocular tumor metabolomics from 1 January 1995, to 12 December 2024. Bibliometric analyses, including publication trends, citation networks, and keyword co-occurrence patterns, were performed using VOSviewer and CiteSpace. Collaborative networks, co-cited references, and keyword burst analyses were mapped to uncover shifts in research focus and global cooperation. Results: Both annual publication volume and citation frequency have shown a wave-like increase since 2000. Initially, research activity was limited during the early period (2000-2006), followed by a phase of slow growth between 2007 and 2015. A surge in publications occurred after 2016, peaking in 2022 with 81 articles. Despite the increase in publications, citation frequency declined after 2019, indicating a gap between research output and scholarly impact. The United States, China, and Italy were the top contributing countries, with the U.S. maintaining a leadership role. Keyword analysis revealed key research themes, including biomarkers, uveal melanoma, and immunotherapy, with a shift towards gene expression, tumor metastasis, and liquid biopsy in recent years. Keyword burst analysis identified retinoblastoma protein and gene expression as major research hotspots. Conclusion: Ocular tumor metabolomics research has made significant strides in recent years. This analysis provides a comprehensive framework for future research, emphasizing the need for interdisciplinary collaborations and the development of non-invasive diagnostic tools to improve the diagnosis, prognosis, and treatment of ocular tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.